8-K: NeuroBo Pharmaceuticals Completes Enrollment for Phase 1 Obesity Trial, Anticipates Data Readouts

NeuroBo Pharmaceuticals has completed enrollment for the single ascending dose (SAD) portion of its Phase 1 clinical trial of DA-1726 for obesity treatment, with top-line data expected in the third quarter of 2024.

Summary

• NeuroBo Pharmaceuticals has finished enrolling participants in the first part of its Phase 1 clinical trial for DA-1726, a drug aimed at treating obesity.
• The trial enrolled 45 participants, who were divided into 5 groups and given either DA-1726 or a placebo.
• The company expects to release initial data from this part of the trial in the third quarter of 2024.
• A second part of the trial, involving multiple doses, is already underway and is expected to have results in the first quarter of 2025.
• NeuroBo is also planning a third part of the trial, with the first patient expected to be dosed in the third quarter of 2025 and results expected in 2026.
• Pre-clinical data suggests DA-1726 may be more effective than existing drugs like semaglutide and tirzepatide, while also preserving lean body mass.

Sentiment

Score: 8

Explanation: The document is positive, highlighting successful enrollment completion, accelerated timelines, and promising pre-clinical data. The company is confident in the potential of DA-1726, which contributes to a strong positive sentiment.

Positives

• The company completed enrollment for the SAD part of the trial without any significant issues.
• The multiple ascending dose (MAD) study has started ahead of schedule.
• Pre-clinical data suggests DA-1726 has the potential to be a best-in-class obesity drug.
• DA-1726 has shown superior weight loss compared to semaglutide and survodutide in pre-clinical models.
• DA-1726 has shown similar weight reduction to tirzepatide while consuming more food in pre-clinical models.
• DA-1726 has demonstrated preservation of lean body mass compared to survodutide in pre-clinical models.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including the ability to execute its commercial strategy and obtain regulatory approvals.
• There is a risk that clinical trial results may not be consistent with pre-clinical data.
• The company's ability to initiate and complete clinical trials on a timely basis is subject to risks.
• The company's ability to recruit subjects for its clinical trials is subject to risks.
• There are risks associated with the license agreement with Dong-A ST Co. Ltd., including potential litigation or regulatory actions.

Future Outlook

The company anticipates top-line data from the SAD Part 1 of the Phase 1 trial in the third quarter of 2024 and from the MAD Part 2 in the first quarter of 2025. They also plan to dose the first patient in Part 3 of the trial in the third quarter of 2025, with interim data in mid-2026 and top-line results in the second half of 2026.

Management Comments

• Hyung Heon Kim, President and CEO, stated that the completion of enrollment marks a key milestone for NeuroBo.
• Mr. Kim noted that no significant issues were encountered during the SAD study, allowing for an accelerated start to the MAD study.
• Mr. Kim believes that DA-1726 may become a best-in-class obesity drug with a better tolerability profile than currently marketed GLP-1 agonists.

Industry Context

The announcement is relevant to the broader trend of developing new treatments for obesity, a significant global health issue. The company is positioning DA-1726 as a potential competitor to existing GLP-1 agonists like semaglutide and tirzepatide, as well as other dual agonists in development.

Comparison to Industry Standards

• The document compares DA-1726 to semaglutide (Wegovy) and tirzepatide (Zepbound), both established GLP-1 agonists for weight loss, suggesting DA-1726 has the potential for superior weight loss.
• The document also compares DA-1726 to survodutide, another dual agonist, highlighting DA-1726's superior weight loss, glucose lowering, and lean body mass preservation in pre-clinical models.
• The company is aiming for a best-in-class profile, suggesting they are targeting results that exceed current industry benchmarks for efficacy and tolerability.

Stakeholder Impact

• Shareholders may view the progress of the clinical trial positively, potentially impacting the stock price.
• Employees may be motivated by the positive progress of the clinical trial.
• Patients with obesity may benefit from the development of a new treatment option.
• The company's suppliers and partners may benefit from the continued development of DA-1726.

Next Steps

• The company will report top-line data from the SAD Part 1 of the Phase 1 clinical trial in the third quarter of 2024.
• The company will report top-line data from the MAD Part 2 in the first quarter of 2025.
• The company plans to dose the first patient in Part 3 of the trial in the third quarter of 2025, pending FDA clearance.
• The company expects an interim data readout from Part 3 in mid-2026 and top-line results in the second half of 2026.

Key Dates

Keywords

DA-1726, obesity, clinical trial, GLP1R, GCGR, oxyntomodulin, weight loss, NeuroBo Pharmaceuticals, Phase 1, semaglutide, tirzepatide, survodutide